Voyager Therapeutics, Inc. Appoints Julie Burek as Principal Financial Officer and Principal Accounting Officer Effective November 26, 2021
November 19, 2021 at 07:48 am EST
Share
On November 16, 2021, Allison Dorval notified Voyager Therapeutics, Inc. of her resignation as Chief Financial Officer of the Company, effective November 26, 2021 to pursue a new role with another company. In connection with the transition of Ms. Dorval, the board of directors of the Company has appointed Julie Burek to assume the roles of principal financial officer and principal accounting officer of the Company, effective as of the Effective Date. Ms. Burek, age 47, has served as the Company's Vice President of Finance since August 2020. Ms. Burek joined the Company as Director, Financial Planning & Analysis in April 2018. Prior to joining the Company, Ms. Burek served in positions of increasing responsibility at Biogen Inc., a biotechnology company, from 2013 to April 2018 including as Associate Director, Finance and Senior Manager, Finance. Prior to her time at Biogen, Ms. Burek served as Senior Finance Manager at EMD Serono Inc., the biopharmaceutical business of Merck KGaA, from 2008 to 2013.
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Companyâs pipeline includes programs for Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Parkinsonâs disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreichâs Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimerâs disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
VOYAGER THERAPEUTICS, INC. 
